Anuh Pharma Q4 FY26: The Bonus Share Illusion and the Missing Cash Flow Drama

Section 1 — At a Glance

The market is currently pricing Anuh Pharma Limited at a market capitalization of ₹770.51 crore, positioning it comfortably within the classic small-cap territory where headline structural adjustments often mask underlying cash flow dynamics. On the surface, the headline numbers for the full financial year ended March 31, 2026, project an image of steady expansion, with annual sales climbing to ₹771.66 crore compared to ₹661.51 crore in the previous fiscal year. However, investor attention must look past this apparent top-line momentum to evaluate a more critical structural shift: the divergence between accounting profits and true cash liquidity.

A sharp warning signal emerges from the annual operational cash flow statement, which flipped into negative territory at -₹3.01 crore for FY26, down from a positive inflow of ₹37.12 crore in FY25. This cash drain occurred despite the company reporting a standalone net profit of ₹41.05 crore for the year. Inventory accumulation and rising receivables have locked up substantial working capital, restricting the company’s internal financial agility. In business, revenue is merely an accounting opinion; actual cash flow is the hard reality.

Furthermore, while the company executed a headline-grabbing 1:1 bonus share issue during the fiscal year, doubling its equity share capital line item to ₹50.11 crore, the fundamental earnings power per share fell. This report analyzes how commoditized drug pricing and working capital asset inflation are testing the limits of Anuh Pharma’s single-location operational blueprint.

Section 2 — Introduction

Anuh Pharma Limited, established in 1960 and part of the broader SK Group, has evolved from a vintage domestic chemical player into a specialized manufacturer of Active Pharmaceutical Ingredients (APIs) and bulk drugs. Operating primarily from its manufacturing base in Maharashtra, the company has historically focused on established, mature chemical molecules where competitive longevity depends on high manufacturing volumes and absolute cost discipline.

Recent strategic moves by management have targeted capacity expansion to support long-term volume growth. The company raised its installed API manufacturing capacity to 2,400 metric tonnes per annum (MTPA) by the close of FY25. However, this structural expansion has coincided with a challenging pricing environment for global bulk chemicals, meaning the business must process larger physical volumes just to sustain its baseline margins. As the company navigates the transition from traditional pharmaceutical manufacturing toward highly regulated international markets, its corporate financial architecture shows a mix of zero operational debt alongside capital locked up in raw material stockpiles.

Section 3 — Business Model: WTF Do They Even Do?

Anuh Pharma operates in the unglamorous, high-volume engine room of the global healthcare industry: manufacturing generic bulk drugs that other companies press into pills. They do not invent blockbusters; they specialize in older, off-patent molecules where they can dominate production volumes.

The company claims world dominance in niche therapeutic areas, operating as the largest producer of pyrazinamide (a core anti-tuberculosis drug) globally, and ranking among the top five producers of erythromycin salts. Its product portfolio is divided between classic macrolide antibiotics, anti-malarials, corticosteroids, and anti-diabetic compounds.

Revenue Mix by Product Category (9MFY24):
├── Erythromycin & Salts: 29%
├── Higher Macrolides: 12%
├── Sulphadoxine & Corticosteroids: 34% (17% each)
├── Gliclazide (Anti-Diabetic): 7%
└── Others (Chloramphenicol, Ambroxol, etc.): 18%

Geographically, the revenue split is evenly balanced, with domestic sales accounting for 55% of the business and exports making up the remaining 45%. Within its export network, Asian markets contribute 43%, followed by Europe at 23% and Africa at 19%. The core business strategy relies on obtaining regulatory approvals, like the European Certificate of Suitability (CEP), to sell these mature chemicals to global generic drug formulators. It is a game of pennies, where any sudden change in raw material costs or shipping rates can turn a profitable quarter into an operational headache.

Section 4 — Financials Overview

Figures are standalone, in ₹ crore. Anuh Pharma does not report consolidated operations as it has no operating subsidiaries or joint ventures as of March 31, 2026.

Quarterly Performance Trend

The numbers show that top-line growth has decoupled from bottom-line profitability. While quarterly sales reached ₹202.12 crore, net profit fell by nearly 24% year-over-year to